Medications for Pulmonary Arterial Hypertension

29 results

  • Adcirca

    (Tadalafil)
    United Therapeutics Corporation
    Usage: ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity. It has been primarily studied in patients with NYHA Functional Class II-III symptoms, including cases of idiopathic or heritable PAH and PAH linked to connective tissue diseases.

  • Alyq (tadalafil)

    (Tadalafil)
    AvKARE
    Usage: Tadalafil is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise ability, primarily in patients with NYHA Functional Class II-III symptoms, including those with idiopathic, heritable PAH, or PAH linked to connective tissue diseases.

  • Alyq (tadalafil)

    (Tadalafil)
    Teva Pharmaceuticals Inc
    Usage: ALYQ® (tadalafil tablets) is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH tied to connective tissue diseases.

  • Ambrisentan (ambrisentan)

    (ambrisentan)
    Sun Pharmaceutical Industries, Inc.
    Usage: Ambrisentan is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening, primarily in patients with WHO Functional Class II–III symptoms and idiopathic, heritable, or connective tissue disease-associated PAH.

  • Ambrisentan (ambrisentan)

    (Ambrisentan)
    Exelan Pharmaceuticals, Inc.
    Usage: Ambrisentan tablets are indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening, primarily in patients with WHO Functional Class II–III symptoms due to idiopathic, heritable PAH, or PAH associated with connective tissue diseases.

  • Bosentan (bosentan)

    (Bosentan)
    Amneal Pharmaceuticals LLC
    Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening in patients with WHO Functional Class II-IV symptoms due to idiopathic or heritable PAH, connective tissue diseases, or congenital heart disease with left-to-right shunts.

  • Bosentan (bosentan)

    (Bosentan)
    Zydus Pharmaceuticals USA Inc.
    Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening, particularly in patients with WHO Functional Class II-IV symptoms related to idiopathic or heritable PAH, connective tissue diseases, and congenital heart disease with left-to-right shunts.

  • Epoprostenol (epoprostenol)

    (EPOPROSTENOL)
    Mylan Institutional LLC
    Usage: Epoprostenol for injection is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, primarily in patients with NYHA Functional Class III-IV symptoms, including those with idiopathic, heritable PAH, or PAH associated with connective tissue diseases.

  • Letairis

    (AMBRISENTAN)
    Gilead Sciences, Inc
    Usage: Letairis is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening, and reduce disease progression and hospitalization risks when combined with tadalafil. It is primarily studied in patients with WHO Functional Class II–III symptoms related to idiopathic, heritable PAH, or connective tissue diseases.

  • Liqrev

    (sildenafil)
    CMP Pharma, Inc.
    Usage: LIQREV is indicated for treating pulmonary arterial hypertension (PAH) in adults (WHO Group I) to improve exercise capacity and delay clinical worsening. Pediatric use information is associated with a different product, REVATIO, and is not included in LIQREV's labeling due to exclusivity rights.